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Abstract 
Introduction:  Guidelines have recommended that structured programs should be introduced to 
support fungal peritonitis in cancer patients. The role of fungi is rare in causing peritonitis, but 
fungal peritonitis has high morbidity and mortality. The abdominal fullness may be secondary to 
the fungi accumulation of peritoneal fluid. The isolation of fungi, particularly Candida, from 
peritoneal fluid samples is an increasingly common occurrence in patients with cancer near 
abdominal region which creates a hypothesis on the role of fungi as a pathogen or an innocent 
bystander in the disease process.  
Materials and methods: In this paper, all the relevant papers about the analysis of clinical signs, 
diagnosis and management fungal peritonitis in cancer patients particularly those near abdominal 
region were reviewed. An extensive search was undertaken of texts published during 1950-2012 
using identified keywords and index terms. 
Results: It seems that tumor-related local factors permit fungi to cross the gut wall and enter the 
peritoneum, resulting in the growth of fungi, inflammation, and weakening of the immune 
system in peritonitis. In this regard, treatment is very difficult due to lack of specific clinical 
signs and difficulty in isolating pathogenic organisms from clinical specimen. 
Conclusion: Examination of peritoneal fluid for the fungal element (direct microscopic exam 
and culture) is necessary in malignant patients with inflammation of peritoneum.    
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Introduction 
Peritonitis is viewed as the inflammation of 
the peritoneum and dependence on the  
 
 
underlying pathology which might be 
infectious or sterile pathogenic.  
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Microorganisms such as gram positive and 
gram-negative bacteria are the main causes 
of peritonitis (1). The role of fungi in 
causing peritonitis is rare, but fungal 
peritonitis (FP) has high morbidity and 
mortality (between 20% -70%) (2-4). 
According to what researches have reported, 
fungi represent about 2% – 23.8% of 
infectious peritonitis (5–8).  Candida species 
are the most common cause of FP (2,5,8). 
Other yeasts and filamentous fungi such as 
Aspergillus, Paecilomyces, Penicillium, and 
Zygomycetes are found, but much less 
frequently. Albicans is the most common 
candida species causing intra-abdominal 
infections, but a shift toward non-albicans 
species such as C. parapsilosis, C. glabrata, 
C. tropicalis, C. krusei, and C. lusitaniae has 
been recently observed (9-11). Penetration 
of fungi in peritonea needs underlying 
conditions. The strongest risk factors for FP 
include peritoneal dialysis (PD) and certain 
co-morbidities such as diabetes or neoplastic 
diseases (12, 13). Malignant conditions, 
particularly near abdominal region, such as 
hepatocellular carcinoma ("liver cancer"), 
cancer metastasized to the liver, and pelvises 
in of gynecologic dissemination cases are 
the risk factors for FP (14, 15). Among 
women, an infected fallopian tube or a 
ruptured ovarian cyst also spreads to 
peritonea and creates localized peritonitis 
(16). 
Virtually, any tumor can cause body fluid 
accumulation, but carcinomas of the lung, 
breast, ovary, and gastrointestinal tract (GI) 
are the most common. Candida species are 
endogenous commensal organisms as part of 
the normal flora of the human mucus 
membranes, gastrointestinal tract, 
respiratory tract, and vagina. According to 
the American Cancer Society, ovarian 
cancer ranks fifth in cancer incidence among 
women by site, superseded by breast, colon, 
rectum, lung, and uterine cancers (17). The 
abdominal fullness may be secondary to the 
fungi accumulation of peritoneal fluid. The 
isolation of fungi, particularly Candida from 
peritoneal fluid samples is an increasingly 
common occurrence in patients with cancer 
near abdominal region that creates a 
hypothesis on the role of fungi as a pathogen 
or an innocent bystander in the disease 
process. Despite this, there still is some 
debate over the importance of positive 
peritoneal fungal cultures and initiation of 
antifungal therapy (18). Furthermore, very 
little research has been published on this 
topic. Therefore, it is important to address 
the role of fungi in peritonitis in patients 
with cancer near abdominal region. The 
purpose of this review was to present the 
latest researches on fungal peritonitis in 
patients with cancer near abdominal region 
and the latest methods of diagnosis and 
treatment to guide clinicians in the 
management of such infections. Candida 
peritonitis associated with peritoneal dialysis 
is not within the scope of this article. 
Epidemiology and risk factors 
FP is classified as primary, secondary or 
tertiary.  Primary FP is spontaneous 
peritonitis with no apparent breach in the 
gastrointestinal (GI) tract and usually occurs 
in immune-compromise patients from 
hematogenous dissemination after chronic 
liver disease (19). Secondary FP is related to 
a pathologic process in a visceral organ, 
such as perforation or trauma, including 
iatrogenic trauma or local infectious process 
within the abdominal cavity. However, 
tertiary FP often develops in the absence of 
the original visceral organ pathology and 
persistent or recurrent infection after 
adequate initial therapy. It’s prognosis is 
worse than a bacterial peritonitis. The 
overall incidence of FP is difficult to 
establish and varies with the underlying 
abdominal disease processes. The disease 
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occurs in both children and adults. 
According to the data, FP makes up 4-10% 
of the peritonitis cases in children and 1-
23% of those in adults in peritoneal dialysis 
(20, 21). Fungi are widely found in human 
environments, being part of the normal flora 
of the skin and mucosa, but in certain 
conditions they can become pathogenic as a 
risk factor. Table 1 shows the major risk 
factors for FP considered in researches. 
 
Table  1. Risk factors associated with Candida peritonitis in cancer patients 
 Hollow viscus perforation 
 Abdominal surgery 
 Thoracic surgery 
 Surgical drains in situ 
 Prolonged time with the intravenous catheter inserted 
 Prolonged time with the urinary catheter inserted 
 Advanced age 
 Presence of an extraperitoneal fungal infection 
 Severe sepsis 
 Previous bacterial peritonitis episodes  
 Wide-spectrum antibiotic treatment in 
previous months    
 Administration of immunosuppressants or 
corticosteroids 
 Prolonged time in the continuous ambulatory 
peritoneal dialysis (CAPD) 
 Intra-abdominal malignancy 
 Presence of immunocompromising or 
debilitating diseases 
 Malnutrition 
 Diabetes 
 Hospitalization 
 Neoplastic diseases 
 
Colonization by fungi such as Candida 
species may occur in patients who have 
received prolonged antibiotic therapy and 
those with an extended hospital stay. This 
flora may be responsible following 
penetrating and causing intra-abdominal 
abscesses. Some fungi can penetrate into the 
peritoneal cavity through intra-luminal or 
peri-luminal pathways and cross the 
intestinal mucosa, or enter through the 
haematogenic pathway due to a distant 
fungal infection. In patients with 
malignancy, receiving cytotoxic or 
corticosteroid drugs and chemotherapy 
cause underlying conditions to ease 
penetration or invade opportunisms fungi in 
tissues. Knowledge of the relation of FP and 
malignancy are essential in understanding its 
medical and public health impact, though 
few studies have been carried out on the 
case. In  recent  years, many reports  have  
stressed  the  increasing  frequency  of  
infection  caused  by  fungal  organisms  in  
patients  with  acute  malignancy (22, 23). 
Although few reports have indicated the 
relationship of intra-abdominal malignancy 
to bacterial peritonitis (24, 25), patients with 
malignancy have an unclear and ower rate of 
FP incidence. In spite of the low incidence 
of FP associated with the malignancy 
underlying condition rather than bacterial 
peritonitis, it has a worse prognosis and can 
be life threatening if not treated properly 
(mortality rate >50%) (1). Malignancy and 
intra-abdominal abscess act as risk factors in 
40-50% of FP patients (26). 
Source and etiological agents  
Table 2 shows the major sources of Candida 
peritonitis in cancer patients. Because of 
tenderness of tissues, swelling, fever, and 
abscesses, FP may occur after the 
penetration or invasion of fungi to the 
abdominal cavity in patients with cancer 
near abdominal regions. Both yeasts and 
filamentous fungi may cause FP. 
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Among the yeasts, strains of the genus 
Candida have the greatest incidence rate in 
FP and are responsible for about 70-90% of 
all cases. Candida albicans has classically 
been considered in predominant species. In 
recent years, other non albicans candida sp. 
such as C. parapsilosis (27), C. krusei (28), 
C. guilermondii (29) and C. glabrata (30) 
were distinguished in FP. Some studies 
reported that other yeasts such as 
Cryptococcus neoformans (31),  
Trichosporon sp. (32), Rhodotorula sp. (33) 
and Pichia ohmeri (34) may be the agents of 
FP. Despite the fact that the filamentous 
fungi are widely found in nature, FP caused 
by molds is a rare clinical problem and they 
often cause problems in patients on 
continuous ambulatory peritoneal dialysis 
(CAPD). They cause FP less than yeasts 
(about 10-30%). They involve peritonea or 
abdominal region tissues after penetration 
into the abdominal cavity.  Peritonitis 
caused by Aspergillus (35), Fusarium (36), 
Acremonium (37), Paecilomyces (38), 
Penicillium (39), Cladosporium (40), 
Exophiala (41), Curvularia (42), and 
Zygomycetes (35) is described in the 
literature.  
Symptoms of disease 
Disease symptoms vary from limited and 
mild disease to systemic and severe disease 
with septic shock. The signs and symptoms 
of FP are similar to those seen in bacterial or 
malignant peritonitis. It is usually suspected 
on clinical grounds with symptoms and 
signs such as swelling and tenderness in the 
abdomen, loss of appetite, cloudy peritoneal 
effluent, abdominal pain, bloating in 
abdomen, fever, low urine output, inability 
to pass stool or gas, nausea and vomiting. In 
some patients, the number of leukocytes was 
below 500/mm3 in peritoneal effluent. The 
number of leukocytes was above 500/mm3 
in only a few numbers of patients (1). FP 
often appears with marked edema or ascites 
in the peritoneal cavity (43). Ascites occurs 
because of problems such as disease in the 
peritoneal cavity which produces excessive 
fluid (infections or cancer).  
Diagnosis  
Fungal peritonitis can be difficult to 
diagnose in patients with cancer. Clinical 
signs and symptoms are nonspecific and 
similar to those seen with bacterial infection. 
The diagnosis of FP can be made by 
visualization of free air or fluid in the 
abdomen on plain radiographs, by cytology, 
and by diagnostic peritoneal lavage. 
Cytological evaluation of abdominal fluid 
can reveal the hallmarks of septic peritonitis. 
Bowel obstruction, bloody effluent, and in 
rare cases a visible fungal colonization of 
the peritoneal catheter may be present 
(mostly with filamentous molds). Peritoneal 
fluid’s gram stain of can help to establish an 
early diagnosis in up to 30% of cases. 
However, the only fungi diagnosis that is 
usually gram-positive on a smear are 
Candida species. Growth rates are generally 
slow in fungal cultures, varying from several 
Table 2. Source of Candida peritonitis in cancer patients 
 Per-cutaneously implanted 
 Hepatic artery catheters 
 Gastrointestinal perforation 
 Anastomotic leakage 
 Bladder perforation 
 Peritoneal dialysis  
 More localized abscesses with association of fungi in 
pelvic inflammatory disease 
 Pancreatitis 
 Peptic ulcer disease 
 Appendicitis 
 Flora of Skin, mucous membrane of the 
gastrointestinal and genital tracts 
 Cancer near abdominal regions 
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days to several weeks, and therefore the 
diagnosis can be considerably delayed. In 
secondary and tertiary FP, Candida species 
are often isolated as leading pathogen fungi 
(44-48). When purulent drainage occurs, an 
exit-site infection with or without erythema 
of the skin is defined. In addition to the 
culture of the peritoneal fluid, any purulent 
discharge from the exit site should be 
swabbed for culture and Gram-stain. FP 
should always be included in the differential 
diagnosis of any other peritonitis, such as 
peritoneal dialysis with cloudy effluent, 
renal or biliary colic, peptic ulcer disease, 
pancreatitis, and acute intestinal perforation. 
A cloudy effluent may be caused by 
chemical inflammation, haemoperitoneum, 
or peritoneal malignancy (49, 50). 
Correct mycological culturing of peritoneal 
effluent is the most important chllenge in 
establishing fungi responsible for FP. 
Identification of organism’s type and 
subsequent antifungal sensitivities will not 
only help selection of antifungal but can also 
indicate the possible source of infection 
(51). 
Aspirate cultures should be carried out for 
any patients with symptoms of peritonitis 
particularly patients with cancer near 
abdominal region, even if the aspirate is 
clear and abdominal pain is absent or 
without an obvious cause (52). Rapid blood-
culture techniques (e.g., BACTEC, Septi-
Chek, BacT/Alert; Becton Dickinson) may 
further speed up isolation and identification. 
The results of serologic tests for systemic 
fungal pathogens are often difficult to 
interpret and may be unreliable. Recent 
diagnostic advances include detection of 
fungal cell-wall components such as 
galactomannan, β-d-glucan, or genomic 
DNA amplified by polymerase chain 
reaction (43, 53 and 54). Those tests may 
improve the diagnostic ability in the future, 
but they are still under investigation. Other 
imaging techniques like positron emission 
tomography scanning may be useful for 
diagnosing and managing FP infection (55). 
Special considerations and literature review 
Although most cases cancer may remain 
silent and invasion of organ wall is usually 
limited to the superficial epithelium, 
extensive tissue necrosis and ulceration 
resulting in cancer tissue perforation is 
possible. Peritonitis is usually caused by the 
spread of an infection into the sterile 
peritoneal environment through organ 
perforation. So, perforation should be 
considered in patients with cancer near 
abdominal region. They have symptoms 
such as unexplained fever, abdominal pain, 
bloating in abdomen, nausea, vomiting, 
pleuritic chest pain, and inability to pass 
stool or gas. Fungal infection of fallopian 
tube or a ruptured ovarian cyst also creates 
localized FP in women (56). Ascites are at 
risk for developing spontaneous fungal 
peritonitis in patients with cancer near 
abdominal region. It is possible that 
irradiation and chemotherapy might have led 
to mucosal disruption, thereby it facilitates 
deeper invasion of the organ by fungi. FP 
has emerged as a relatively common 
infection in patients who receive peritoneal 
dialysis, ventriculoperitoneal shunt or intra-
peritoneal delivery of chemotherapy. Also, 
FP has been reported among malignant 
patients, particularly those with cancer near 
abdominal region or those receiving 
chemotherapy medications in the setting of 
disseminated disease. 
Among the fungal pathogens, Candida sp is 
frequently isolated from the ascitic fluid of 
patients with perforated ulcers. On the other 
hand, fungi (yeast or mold) can aggravate 
ulcer perforation where they exist as a 
commensally opportunistic organism (57). 
FP has also been rarely associated with 
patients who have recently had oral or upper 
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gastrointestinal tract bleeding (58). Many of 
these patients do not show clear signs of 
peritonitis or some of these patients might 
have been previously diagnosed with other 
kinds of sites. There have been some 
previous reported cases of FP in patients 
with cancer. Most of these occur 
predominantly in patients with solid tumors, 
such as gastrointestinal tract or 
genitourinary tract cancer. 
Gerald P. Bodey (1966) recorded 189  
fungal infections  in  161  patients  with  
acute  leukemia  during  a  10.5-year period. 
Severe  Candidiasis  occurred  in  71  
patients  and  62  patients  had  only  focal 
gastrointestinal  lesions. Candida spp. was 
the major agent of infections. 
Approximately, one-half of the Candida 
infections were localized to the 
gastrointestinal tract. He explained two 
cases, which resulted in perforation of 
Candida and Rhizopus from abdominal 
infection. He reported increased incidence of 
fungal disease in patients with acute 
leukemia  related  to  the  use  of  anti-
leukemia  agents,  adrenal  corticosteroids  
and  antibiotics (59). 
Singer C. et al (1977) studied 364 episodes 
of bacteremia and fungemia in patients with 
neoplastic disease (leukemia or lymphoma) 
at Memorial Sloan-Kettering Cancer Center 
during a 14 month period. They found 13 
episodes candidemia. The patients had 
underling condition or signs such as 
abdominal infection, catheter-related 
infections and symptoms of peritoneal 
inflammation (60).  
Kopelson G. et al (1979) reported two 
patients with intra-abdominal malignancy 
that developed isolated Candida albicans 
peritonitis. They postulated tumor-related 
local factors permitting fungi to cross the 
gut wall and enter the peritoneum. Also, 
they concluded that patients who develop 
fungal peritonitis may have a primary or 
metastatic intra-abdominal malignancy and 
fungi should be considered as a cause of 
peritonitis in cancer patients (61). 
Martino R. et al (1997) in their study, titled 
“reactivation of invasive fungal infection in 
patients with hematologic malignancy” 
studied 17 patients with a previous invasive 
fungal infection (IFI) due to Aspergillus 
during 4 years, Pseudallescheria boydii or 
Candida Spp. 18 had an underlying 
hematologic malignancy and received 
further intensive chemotherapy. Eight 
patients died. They concluded that these 
patients might have risked for reactivation of 
IFI (62). 
C. Viscoli et al (1999) recorded 249 
episodes in a surveillance study of 
candidemia in cancer patients. Candida 
albicans was isolated in 70% of cases 
involving patients with solid tumors and in 
36% of hematologic disease.  Solid tumors 
were mainly located in the genitourinary 
tract (29%) and the gastrointestinal tract 
(29%). Clinically or microbiologically 
documented organ involvement was present 
in only 24 patients (10%) and 3 patients 
(12.5%) had shown peritonitis (63). 
M. O. Almoujahed et al (2003) reported 33 
cases of fungal peritonitis during a 4-year 
period (5.3% of all microbiology reports). 
Neoplastic conditions and human 
immunodeficiency virus infection were 
present in some patients as underlying 
conditions (16% and 3.2%). They explained 
percutaneously implanted catheters in 15 
cases, gastrointestinal perforation or 
anastomotic leakage in 15 cases and bladder 
perforation in one case where the source of 
peritonitis involved. Candida spp. (93.8%), 
Trichosporon pullulans (3.1%) and 
unidentified yeast (3.1%) were isolated from 
them (64). 
Thomas D W. et al (2005) reported Candida 
albicans peritonitis in a patient with Felty’s 
syndrome (a syndrome consists of 
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rheumatoid arthritis, splenomegaly, and 
neutropenia) who had skipped ulcers with 
fungal hyphae. They presumed that when 
host defenses are compromised, fungal 
invasive disease might associatively occur 
with other predisposing factors such as 
corticosteroids and antibiotic treatments 
(65). 
P. Montravers et al (2006) in study of 
mortality in peritonitis recorded that among 
164 patients with signs of nosocomial 
peritonitis (NP), 84 (51%) had malignancy 
and immunosuppression as an underlying 
disease. Also they explained the 
significantly increased mortality and 
morbidity observed in the group of NP with 
Candida isolation in the peritoneal fluid. It 
shows the pathogenic role of Candida (66). 
Afridi SP. et al (2008) studied 300  
perforation peritonitis in patients who had 
pain in abdomen, abdominal distention, 
altered bowel habit, nausea vomiting, fever 
and shock due to septicemia. The most 
common cause of perforation peritonitis 
noticed in their series was acid peptic 
disease (45%) and the mortality was 10.6%. 
Among the patients, 33 (11%) cases had a 
malignancy as underlying diseases and 2.6% 
showed peritonitis. They recorded that the 
perforation is a rare complication of gastric 
carcinoma (less than 1%), but perforated 
gastric ulcer has a high malignancy 
incidence of. As seen in their study, out of 7 
gastric perforations 2 were malignant (67). 
P. Montravers et al (2010) studied detailed 
prospective of 271 ICU patients with proved 
to have invasive Candida infection. They 
reported that, 26 (9.6%) of these patients 
had candidemia and 93 (34.3%) had 
Candida peritonitis. Mortality was 38% in 
ICU. Among patients with peritonitis, 36% 
had solid tumor, 4% hematological 
malignancy, 11% immunosuppression and 
12% Chronic renal failure, while 90% used 
central venous catheter and 89% urinary 
catheter (68). 
Prophylaxis  
In order to find a probable relationship 
between FP and cancer near abdominal 
region, the use of antifungal prophylaxis 
such as oral nystatin or fluconazole seems to 
be a logical approach. National 
Comprehensive Cancer Network (NCCN) 
clinical practice guidelines in oncology for 
prevention and treatment of infections in 
Patients with Cancer which highlights the 
importance of antifungal prophylaxis as a 
key therapeutic strategy in the management 
of high risk patients for invasive fungal 
infections. Risk factors can be undergoing 
chemotherapy for acute myelogenous 
leukemia or myelodysplastic syndromes, or 
stem cell transplantation (69) since these 
infections are major causes of death in these 
seriously ill patients. However, some studies 
show that the prophylaxis given during other 
therapies in patients with cancer has yielded 
conflicting results (70-72). So, until the 
results of larger randomized trials is 
available, the guidelines from the 
International Society for Peritoneal Dialysis 
(ISPD) recommend antifungal prophylaxis 
only in centers with high FP rates. For 
programs with lower rates, there is no clear 
message, and decisions have to be made on 
an individual basis (1). Management Despite 
improved diagnostic techniques, potent 
pharmaceutical antifungal, modern intensive 
care, and aggressive surgical treatment, up 
to one third of patients still die of severe 
secondary FP. As FP’s clinical signs and 
symptoms are nonspecific and similar to 
other kind of peritonitis, immediate medical 
management should include correction of 
metabolic and acid-base imbalances. Fluid, 
colloid, and electrolyte replacement with an 
isotonic solution are the major focus of 
medical management. Analgesics and 
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antiemetic are administered for pain, nausea 
and vomiting. Patients’ blood pressure 
and urine output should be monitored 
frequently and the character of drainage 
should be observed and recorded. Mortality 
of FP correlates with the severity of disease 
and it’s underlying conditions, so that 
improving the underlying conditions are 
necessary. Broad-spectrum antibiotic 
therapy usually is initiated immediately. 
Drainage of the abdomen may be 
accomplished by placement of peritoneal 
drains or by open abdominal management. 
Commercial peritoneal catheters seem a 
preferable method of providing continuous 
drainage; omentectomy must be performed 
to allow any drains to function. If culture 
results showed fungal growth and drug 
sensitivity was determined to fungi, 
antifungal therapy should be initiated 
immediately. Antifungal drug is 
administered intravenously, but they may 
also be infused directly into the peritoneum. 
If one or more agents are actually isolated, 
therapy will indeed be targeted at them. The 
selection or doses and combinations of 
antifungal therapy are not the same and vary 
based on case series and opinions. 
Prescription of antimycotics can be 
intraperitoneal, intravenous, or oral. If the 
catheter is removed, the switch to systemic 
therapy will be necessary. 
For initial therapy, most clinicians prefer to 
start with fluconazole, intraperitoneally (200 
mg in 1 exchange every 24 – 48 hours) 
intravenously or orally (100 – 200 mg daily) 
because it is well absorbed from the 
gastrointestinal tract and has a good 
intraperitoneal penetration. Fluconazole 
might be used either alone or in combination 
with other antifungal drugs such as 
flucytosine. But some species of mycotic 
agents such as non-albicans Candida 
species may be resistant to it (73). In these 
cases, a switch to amphotericin or a newer 
azole might be required. Since the fungi’s 
resistance risk to Flucytosine is so high, it is 
recommended not to prescribe it alone. 
However, after oral dosage (500 mg twice 
daily), the peritoneal penetration is effective. 
On the other hand, it has toxic activity on 
bone marrow and liver. So, it should not be 
used in patients with bone marrow 
depression, hematologic, or hepatic disease. 
patients who are immunosuppressed or had 
significant prior exposure to azoles or if the 
pathogen agent is more resistant to 
fluconazole (e.g., Candida glabrata, 
Candida krusei), intravenous deoxycholate 
or lipid-associated amphotericin B is a 
chosen drug (0.5 mg/kg to 1 mg/kg daily 
depending on yeasts or mold pathogen). 
However, mortality is reported as high as 
70% in patients who have undergone 
surgical intervention, though they had 
received amphotericin B (74, 75). 
Combination therapy with amphotericin B 
and either fluconazole or flucytosine has 
been used successfully (76, 77). There are 
very limited experiences with the newer 
antifungal agents such as newer triazole (e.g. 
voriconazole and posaconazole) and 
echinocandins (e.g. Caspofungin, 
micafungin, and anidulafungin). 
Voriconazole can be used into oral and 
intravenous administration and its effects 
may yeast filamentous fungi except 
Zygomycetes. Oral posaconazole has proven 
effective in the case of FP due to 
Zygomycetes (78). As both agents carry a 
risk of hepatotoxicity, monitoring liver 
function is recommended in treated patients. 
The role of echinocandins in FP has not yet 
been defined. But their broad-spectrum 
activity and safety characteristics might 
make these agents as an important 
therapeutic alternative to amphotericin B in 
patients with peritonitis resulting from 
infection with moulds and some non-
albicans Candida yeasts or in patients 
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intolerant to other antifungal therapies. 
There is no consensus on the duration of FP 
treatment; however, most investigators 
advocate at least 2 weeks of therapy with the 
possibility of 4 or more weeks in certain 
clinical situations. Many investigators 
believe that the catheter has a role in the 
incidence of fungal peritonitis particularly in 
patients who have failed medical therapy 
alone (79- 81). If patients have a catheter, 
after an outbreak symptom of FP and fungi 
identified by microscopy or culture, NCCN 
guideline suggest that the catheter should be 
removed immediately in adults because 
fungi can be colonized. It forms biofilm and 
spreads on the catheter surface. Due to 
facility of vigorous peritoneal lavage with 
drugs, some recent pediatric reports were 
been promoted early but not immediately 
removed (82-84). The classical single 
operation for FP, which obliterates the 
source of infection and purges the peritoneal 
cavity, may be inadequate for severe forms 
of peritonitis. For the latter, more aggressive 
surgical techniques are necessary to 
decompress increased intra-abdominal 
pressure and prevent or treat persistent and 
recurrent infection. There is an increasing 
evidence that laparoscopy may play a 
definite role in patients with FP. As a result 
of perforated diverticular disease, treatment 
by laparoscopy and peritoneal lavage was 
successful in patients with generalized 
peritonitis. However, laparoscopic 
management of generalized peritonitis needs 
further assessment.  
Summary  
FP infection is increasingly important in 
clinical practice in patients with  
cancer near abdominal region. There was an 
association between perforation of the 
cancer tissues in patients and fungal 
peritonitis. Based on a limited number of 
published clinical experiences on the topic, 
it is estimated that less than 2% of patients 
with cancer near abdominal region involved 
FP. However, its importance resides in the 
disproportionately greater morbidity and 
mortality that has historically been 
associated with this infection. Several 
factors appear to predispose patients to the 
development of FP. The most consistently 
reported factor in these patients is the use of 
cytotoxic or corticosteroid drugs and 
chemotherapy or a catheter-related infection 
prior to the development of the fungal 
infection. Typically, Candida species 
account for the majority of fungal isolates, 
with C. albicans being the most common. 
Presumably, perforation of the cancer tissues 
helps in penetration of fungi from the 
gastrointestinal or genital tracts and 
overgrowth of them into the peritoneal 
cavity. The decision for empirical antifungal 
treatment in any patient with suspected FP 
has to be based on the exact knowledge 
regarding origin, severity of disease, 
knowledge of patient specific risk factors, 
and previous exposure to antifungal drugs. 
The optimal approach to the treatment of FP 
remains undetermined. Medical therapy of 
FP most often consists of a combination of 
antifungal medication, catheter removal and 
surgical techniques. The fact is that FP must 
be considered in all patients, especially 
malignant patients with symptoms of 
peritonitis and those unresponsive to the 
routine antibiotic therapy. 
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